Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | HRH1 | P35367 | 2/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11484706 | 0.92 | CHRM3 (0.58) | CHRM2CHRM3KCNH2LMNACYP2D6 | |
| SCHEMBL17294651 | 0.85 | CHRM3 (0.60) | CHRM2CHRM3KCNH2LMNACYP2D6 | |
| SCHEMBL5163430 | 0.82 | CHRM3 (0.65) | CHRM2CHRM3KCNH2LMNACYP2D6 | |
| Hydrochloric Acid SCHEMBL16274988 | 0.81 | CHRM3 (0.63) | CHRM2CHRM3KCNH2LMNACYP2D6 | |
| SCHEMBL27681368 | 0.80 | CHRM3 (0.74) | CHRM2CHRM3KCNH2LMNACYP2D6 | |
| SCHEMBL14526652 | 0.77 | CHRM3 (0.61) | CHRM2CHRM3KCNH2CYP2D6CYP2C19 | |
| SCHEMBL1999952 | 0.77 | CHRM3 (0.61) | CHRM2CHRM3KCNH2CYP2D6CYP2C19 | |
| SCHEMBL16759127 | 0.77 | CHRNA7 (0.55) | CHRM2CHRM3CHRM1CHRM4 | |
| SCHEMBL11465571 | 0.76 | CHRM3 (0.60) | CHRM2CHRM3KCNH2CYP2D6CYP2C19 | |
| SCHEMBL5160650 | 0.76 | KEAP1 (0.42) | CHRM2CHRM3KCNH2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | claimed |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-11-23 | — | — | US | claimed |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2017-06-29 | — | — | US | claimed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | claimed |
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| EP-3148518-B1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PRIVATE LTD (IN) | 2022-11-30 | — | — | EP | disclosed |
| CN-106659697-B | Compounds as antituberculosis agents | 斯菲叶尔制药私有公司 | 2022-03-29 | — | — | CN | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-10207993-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| US-10100012-B2 | Compounds as anti-tubercular agents | SPHAERA PHARMA PVT. LTD. (IN) | 2018-10-16 | — | — | US | disclosed |
| EP-3148518-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | Sphaera Pharma Pvt. Ltd. (IN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015181837-A2 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | SPHAERA PHARMA PVT. LTD. (IN) | 2015-12-03 | — | — | WO | disclosed |
| EP-1275645-B1 | LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM | HAMAMATSU PHOTONICS KK (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-6649142-B2 | Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system | HAMAMATSU PHOTONICS K.K. (JP) | 2003-11-18 | — | — | US | disclosed |
| US-20030113261-A1 | Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system | HAMAMATSU PHOTONICS K.K. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1275645-A1 | LABELED COMPOUNDS FOR MEASURING THE FUNCTION OF THE MUSCARINIC ACETYLCHOLINE NERVOUS SYSTEM | HAMAMATSU PHOTONICS K. K. (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030113261-A1 | Labeled compounds for measuring the function of the muscarinic acetylcholine nervous system | CHRM3, CHRM5, CHRM2 | CHRM2 3/4885CHRM3 1/4885KCNH2 256/4885 |
| US-10100012-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | CHRM2 2407/4885CHRM3 2760/4885KCNH2 4552/4885 |
| US-10207993-B2 | Compounds as anti-tubercular agents | FNTB, G6PD, PGGT1B | CHRM2 2407/4885CHRM3 2760/4885KCNH2 4552/4885 |
| US-20170334851-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CHRM2 2458/4885CHRM3 2635/4885KCNH2 4608/4885 |
| US-20170183305-A1 | NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS | FNTB, PGGT1B, GGPS1 | CHRM2 2458/4885CHRM3 2635/4885KCNH2 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.